Patents by Inventor Rene Belder

Rene Belder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING COMPLEMENT-MEDIATED DISEASES
    Publication number: 20240025978
    Abstract: Provided herein are methods of treating cold agglutinin disease (CAD) or chronic inflammatory demyelinating polyneuropathy (CIDP) in a subject in need thereof. The methods comprise administering to a subject a humanized antibody that specifically binds complement component C1s (anti-C1s antibody). Methods of treating CAD comprise administering the anti-C1s antibody to a subject in a fixed dose. Methods of treating CIDP comprise administering to a subject a weight-based loading dose of the anti-C1s antibody followed by one or more fixed maintenance doses. The methods comprise administering an effective dose of anti-C1s antibody to achieve a minimum level of CP inhibition for therapeutic effect.
    Type: Application
    Filed: June 23, 2023
    Publication date: January 25, 2024
    Applicant: Bioverativ USA Inc.
    Inventors: Miguel Alonso Alonso, Nazem Atassi, Rene Belder, Timothy Wing Yau Chow, Pirouz Shamszad, Michael John Storek, Christopher Lawrence Vinnard, Erik Holger Wallstroem, Yu Jyu Nancy Wong
  • Treatment of type 2 diabetes mellitus patients
    Patent number: 10159713
    Abstract: The present invention refers to lixisenatide for use in the reduction of progression of urinary albumin excretion in a type 2 diabetes mellitus patient.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: December 25, 2018
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Rene Belder, Peter Johnston, Francesca Lawson, Lin Ping, Xiaodan Wei
  • METHOD FOR TREATING CHRONIC INFLAMMATORY DISEASES
    Publication number: 20180344705
    Abstract: Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
    Type: Application
    Filed: March 28, 2018
    Publication date: December 6, 2018
    Inventors: Jinkun Zhang, Zofia E. Dziewanowska, Rene Belder, Ian Henderson, Joseph B. Bogardus, Zhaoying Zhang
  • Treatment of Type 2 Diabetes Mellitus Patients
    Publication number: 20180243379
    Abstract: The present invention refers to lixisenatide for use in the reduction of progression of urinary albumin excretion in a type 2 diabetes mellitus patient.
    Type: Application
    Filed: February 9, 2018
    Publication date: August 30, 2018
    Inventors: Rene Belder, Peter Johnston, Francesca Lawson, Lin Ping, Xiaodan Wei
  • Method for treating disorders associated with glomerular function
    Patent number: 9993461
    Abstract: Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: June 12, 2018
    Assignee: Ligand Pharmaceuticals Inc.
    Inventors: Jinkun Zhang, Zofia E. Dziewanowska, Rene Belder, Ian Henderson, Joseph B. Bogardus, Zhaoying Zhang
  • METHOD FOR TREATING DISORDERS ASSOCIATED WITH GLOMERULAR FUNCTION
    Publication number: 20170354646
    Abstract: Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 14, 2017
    Inventors: Jinkun Zhang, Zofia E. Dziewanowska, Rene Belder, Ian Henderson, Joseph B. Bogardus, Zhaoying Zhang
  • Method for treating glomerulosclerosis
    Patent number: 9662312
    Abstract: Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: May 30, 2017
    Assignee: Ligand Pharmaceuticals Inc.
    Inventors: Jinkun Zhang, Zofia E. Dziewanowska, Rene Belder, Ian Henderson, Joseph B. Bogardus, Zhaoying Zhang
  • Treatment of Type 2 Diabetes Mellitus Patients
    Publication number: 20160296601
    Abstract: The present invention refers to lixisenatide for use in the reduction of progression of urinary albumin excretion in a type 2 diabetes mellitus patient.
    Type: Application
    Filed: March 17, 2016
    Publication date: October 13, 2016
    Inventors: Rene Belder, Peter Johnston, Francesca Lawson, Lin Ping, Xiaodan Wei
  • ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY
    Publication number: 20150164865
    Abstract: Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
    Type: Application
    Filed: February 25, 2015
    Publication date: June 18, 2015
    Inventors: Jinkun Zhang, Zofia E. Dziewanowska, Rene Belder, Ian Henderson, Joseph B. Bogardus, Zhaoying Zhang
  • ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY
    Publication number: 20140142149
    Abstract: Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
    Type: Application
    Filed: December 19, 2012
    Publication date: May 22, 2014
    Applicant: Ligand Pharmaceuticals Inc.
    Inventors: Jinkun Zhang, Zofia E. Dziewanowska, Rene Belder, Ian Henderson, Joseph B. Bogardus, Zhaoying Zhang
  • Pharmaceutical compositions
    Publication number: 20030125379
    Abstract: The instant invention provides methods and pharmaceutical compositions for reducing LDL cholesterol levels in mammals comprising the administration of a therapeutically effective amount of greater than 40 mg once per day of pravastatin, or a pharmaceutically acceptable salt or ester thereof, to a mammal in need of such treatment.
    Type: Application
    Filed: November 26, 2002
    Publication date: July 3, 2003
    Inventors: Rene Belder, Mark E. McGovern
  • Synergistic combination of pravastatin and aspirin and method
    Publication number: 20030013688
    Abstract: A synergistic combination of pravastatin and aspirin is provided which is formed of 40 mg pravastatin and 81 mg or higher of aspirin, preferably 81 mg aspirin or 325 mg of aspirin. A method for preventing, inhibiting or reducing risk of onset of cardiovascular events or cerebrovascular events employing such synergistic combination is also provided.
    Type: Application
    Filed: April 23, 2002
    Publication date: January 16, 2003
    Inventors: Rene Belder, Kannan Natarajan
  • Pharmaceutical compositions
    Publication number: 20020183383
    Abstract: The instant invention provides methods and pharmaceutical compositions for reducing LDL cholesterol levels in mammals comprising the administration of a therapeutically effective amount of greater than 40 mg once per day of pravastatin, or a pharmaceutically acceptable salt or ester thereof, to a mammal in need of such treatment.
    Type: Application
    Filed: February 27, 2001
    Publication date: December 5, 2002
    Inventors: Rene Belder, Mark E. McGovern